

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): October 6, 2025

InfuSystem Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-35020
(Commission File Number)

20-3341405
(I.R.S. Employer Identification Number)

**3851 West Hamlin Road
Rochester Hills, Michigan 48309**
(Address of principal executive offices) (Zip Code)

(248) 291-1210
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, par value \$.0001 per share	INFU	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 - Regulation FD Disclosure

InfuSystem Holdings, Inc. (the “Company”) hereby furnishes the information set forth in the Investor Presentation dated October 6, 2025 , which is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 — “Regulation FD Disclosure” of this Current Report on Form 8-K and the Investor Presentation attached hereto as Exhibit 99.1 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	<u>InfuSystem Holdings, Inc. Investor Presentation dated October 6, 2025</u>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.


By:

/s/ Barry Steele

Barry Steele

Chief Financial Officer

Dated: October 6, 2025



Helping People Live Longer and Healthier Lives

Investor Presentation

October 6, 2025 | (NYSE American: INFU)

Forward-Looking Statements / Non-GAAP Measures

Forward-Looking Statements

Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "goal," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for the new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, the Company's ability to remediate its previously disclosed material weakness in internal control over financial reporting, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company's most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this presentation speak only as of the date hereof. InfuSystem does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Non-GAAP Measures

This presentation contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this presentation provide useful information to the Company's management, investors and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for nonrecurring or non-core items that are not part of the normal course of business and that the Company's management does not believe will have similar comparable year-over-year items. A reconciliation of those measures to the most directly comparable GAAP measures is provided in Appendix A of this presentation.

Investment Highlights

39-Year History | Long-Term Blue Chip Customer Base



6

Six Consecutive Years of Record Revenue

- Revenue CAGR: 12%
- Adjusted EBITDA CAGR: 11%

2024 Adjusted EBITDA: \$25.3M

Business Generates Substantial Annual Cash Flow

- \$20.5M – 2024 Cash Flow Provided by Operations

Solid Balance Sheet to Support Growth*

- Net Leverage Ratio: 0.86x
- Debt/Equity Ratio: 0.85x

Medical Equipment Assets*: ~\$111M

NOLs: ~\$14.4M

*Data as of June 30, 2025, unless otherwise noted

Business Highlights



A leading provider of medical equipment and patient services powered by a **100K+ device fleet** in the U.S. and Canada



Nearly four decades of experience, built on existing Oncology therapy model and now rapidly expanding into multiple therapies



National scale, **serving 19 out of 20 top-ranked hospital systems** nationwide*

Participating in-network provider in **more than 800** health insurance networks covering **over 96%** of the U.S. population, serving **over 2,000** sites of care



Serving nearly **4,500 customer locations**




Seven major service areas in the U.S. and Canada with **more than 500 employees**



*Source: Newsweek, World's Best Hospitals 2024

Providing Solutions To Manage the Device Throughout the Treatment Cycle

Device-Agnostic Services Platform That Improves Health Care Processes and Outcomes



Patient Services

- Oncology • Pain Management
- Wound Care

Device Solutions

- Biomedical Services • Consumables
- Inventory Management • Sales, Rentals & Leasing



Competitive Advantages

- Significant Barriers to Entry in Patient Services
- Service-Based Competitive Advantages in Device Solutions

Patient Services

- 800+ national payer contracts covering over 96% of U.S. population
- Focused and scalable revenue cycle management team
- 24/7 clinical hotline
- Device agnostic




Device Solutions

- White Glove Concierge approach
- 7 facilities serving U.S. and Canada
- More than 200 biomedical technicians
- Extensive repair capabilities and expertise
- ISO 9001/13485 certified

Patient Services

Unique High-Service Platform, Third-Party Payer Model
INFU Is Paid by the Patient's Insurance Provider



- Oncology (Core Business) Is Profitable and Stable
- Growth Opportunities Are Pain Management and Wound Care

Device Solutions


Traditional Medical Distribution, Direct Payer Model
INFU Is Paid Directly by the Hospital/Clinic/Home Care Provider



- Device Solutions (Core Business) Is Stable and Growing
- Growth Opportunity Is Biomedical Services


Managing the Device Throughout the Treatment Cycle

Connecting and Enhancing Processes for Key Stakeholders To Solve Complex Problems




High-Value Health Care Services Platform

Specialized Skills We Developed for Oncology Now Being Leveraged in New Therapies and Partnerships



InfuSystem's Unique Capabilities Are in High Demand




Quarterly Trends

Net Revenue Quarterly Trend






Adjusted EBITDA Quarterly Trend (1)(2)



(1) See Appendix A.

(2) Includes \$0.7M spent in 2024 on replacement of our main enterprise resource planning application ("ERP"), and an estimated \$2.5M in 2025. Expected completion in 2026.

Annual Financial Performance






(1) See Appendix A.

(2) Includes \$0.7M spent in 2024 on the replacement of ERP application, and an estimated \$2.5M in 2025. Expected completion in 2026.

*2020 includes favorable COVID-19 impact on Net Revenue and AEBITDA.

**Estimates as of June 30, 2025

Annual Margin Performance




(1) See Appendix A.

(2) Includes \$0.7M spent in 2024 on the replacement of ERP application, and an estimated \$2.5M in 2025. Expected completion in 2026.

*2020 includes favorable COVID-19 impact on AEBITDA.

**Estimates as of June 30, 2025

Capital Expenditures & Revenue Growth – TTM




Balance Sheet Highlights

\$ in Millions	As of June 30, 2025
Equity	\$54.5
Total Long-Term Debt ¹	\$26.3
Net Leverage Ratio	0.86x
Debt/Equity Ratio	0.85x
Total Available Liquidity	\$49.1
Cash Provided by Operations (TTM)	\$26.6
Cash (Designed for low cash levels)	\$0.7
Working Capital	\$18.2
NOLs	\$14.4


(1) July 15, 2025, we amended the 2021 credit agreement. New expiration date July 15, 2030.

Fixed vs. Floating Debt



Fixed portion of debt effected through interest-rate swaps.

Capital Allocation Priorities



Investments to Drive Organic Growth Initiatives

- Device Solutions – Biomedical Services
- Patient Services – SI Health Care Technologies



Reduce Debt Levels

- Ongoing Financial Flexibility
- Maintain Leverage at 1.5x – 2.0x



Share Repurchase – Opportunistic

- \$20M Stock Repurchase Program Renewed May 20, 2024, Expires on June 30, 2026
- Purchased \$7.6 M of Shares as of June 30, 2025
- Purchased \$6.2 M of Shares Under Previous Program*

*Previous Authorization Was from June 30, 2021 to May 20, 2024

Corporate Priorities



Maintain Solid Core Business in Oncology and Device Solutions



Drive Major Growth Initiatives – Biomedical and Wound Care



Continuous Process Enhancements to Boost Net Margins; Sustain Optimal CapEx Efficiency



Balance Investment/Growth Initiatives With Improving AEBITDA and Cash Flow

Appendix A GAAP to NON-GAAP Reconciliation

NET INCOME TO ADJUSTED EBITDA:

(in thousands)	Twelve Months Ended December 31,				Six Months Ended June 30,	
	2021	2022	2023	2024	2024	2025
GAAP net income (loss)	\$ 1,420	\$ 18	\$ 872	\$ 2,345	\$ (395)	\$ 2,332
Adjustments:						
Interest expense	1,377	1,402	2,170	1,777	940	709
Income tax (benefit) provision	(163)	112	979	2,714	405	1,367
Depreciation	10,363	10,866	11,518	11,508	5,438	6,166
Amortization	4,262	2,494	990	991	495	495
Non-GAAP EBITDA	\$ 17,259	\$ 14,892	\$ 16,529	\$ 19,335	\$ 6,883	\$ 11,069
Stock compensation costs	6,404	3,825	4,074	4,460	2,055	1,769
Medical equipment reserve and disposals (1)	194	1,162	1,501	573	127	315
Acquisition costs	154	—	—	—	—	—
SOX readiness costs	199	110	—	—	—	—
Management reorganization/transition costs (2)	49	633	72	108	108	1,055
Cooperation Agreement payment and associated legal expenses	—	—	16	649	649	—
Certain other non-recurring costs	(210)	123	174	175	109	141
Non-GAAP Adjusted EBITDA	\$ 24,049	\$ 20,745	\$ 22,366	\$ 25,300	\$ 9,931	\$ 14,349
Business Application ("ERP") Upgrade Investment (3)	\$ —	\$ —	\$ —	\$ —	\$ 51	\$ 1,098

(1) Amounts represent a non-cash expense recorded to adjust the reserve for missing medical equipment and/or the disposal of medical equipment and is being added back due to its similarity to depreciation.

(2) Includes severance compensation for the outgoing CEO totaling \$1.0 million for the period ending June 30, 2025.

(3) Represents expenses associated with a project to upgrade the Company's information technology and business applications including a replacement of our main enterprise resource planning ("ERP") application. The project was launched during the second quarter of 2024 and is expected to be completed during the first quarter of 2026. Amounts are included in GAAP net income and have not been added back in the measurement of Non-GAAP Adjusted EBITDA.

